You just read:

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease

News provided by

Takeda Pharmaceutical Company Limited

27 May, 2014, 15:43 BST